Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 25071768)

1.

Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.

Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, Specht HM, Multhoff G.

Front Immunol. 2014 Jul 1;5:307. doi: 10.3389/fimmu.2014.00307. eCollection 2014.

2.

Elevated serum levels of heat shock protein 70 are associated with breast cancer.

Gunaldi M, Afsar CU, Okuturlar Y, Gedikbasi A, Kocoglu H, Kural A, Akarsu C, Gunduz U, Tiken EE.

Tohoku J Exp Med. 2015;236(2):97-102. doi: 10.1620/tjem.236.97.

3.

Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial.

Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, Tokumitsu Y, Hashimoto N, Tokuhisa Y, Sakamoto K, Sakai K, Suehiro Y, Hinoda Y, Tamada K, Yoshino S, Hazama S, Oka M.

Cancer Immunol Immunother. 2015 May 16. [Epub ahead of print]

PMID:
25982372
4.

Circulating mortalin autoantibody-a new serological marker of liver cirrhosis.

Lu WJ, Saxena N, Luk JM, Kaul SC, Wadhwa R.

Cell Stress Chaperones. 2015 Jul;20(4):715-9. doi: 10.1007/s12192-015-0592-1. Epub 2015 Apr 24.

PMID:
25905813
5.

Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.

Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, Xu Q, Chen X.

Int J Med Sci. 2015 Feb 15;12(3):256-63. doi: 10.7150/ijms.10735. eCollection 2015.

6.

The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation.

Multhoff G, Pockley AG, Schmid TE, Schilling D.

Cancer Lett. 2015 Feb 11. pii: S0304-3835(15)00104-4. doi: 10.1016/j.canlet.2015.02.013. [Epub ahead of print]

7.

ROS production, intracellular HSP70 levels and their relationship in human neutrophils: effects of age.

Kovalenko EI, Boyko AA, Semenkov VF, Lutsenko GV, Grechikhina MV, Kanevskiy LM, Azhikina TL, Telford WG, Sapozhnikov AM.

Oncotarget. 2014 Dec 15;5(23):11800-12.

8.

Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma.

Miyahara K, Nouso K, Dohi C, Morimoto Y, Kinugasa H, Wada N, Takeuchi Y, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Amano M, Nishimura SI, Yamamoto K.

Hepatol Res. 2014 Dec 12. doi: 10.1111/hepr.12441. [Epub ahead of print]

PMID:
25495282
9.

A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.

Reis H, Pütter C, Megger DA, Bracht T, Weber F, Hoffmann AC, Bertram S, Wohlschläger J, Hagemann S, Eisenacher M, Scherag A, Schlaak JF, Canbay A, Meyer HE, Sitek B, Baba HA.

Biochim Biophys Acta. 2015 Jun;1854(6):641-50. doi: 10.1016/j.bbapap.2014.10.024. Epub 2014 Nov 5.

PMID:
25448011
10.

Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma.

El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H.

World J Hepatol. 2014 Nov 27;6(11):818-24. doi: 10.4254/wjh.v6.i11.818.

11.

Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.

Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y, Nezu R, Kuzushita N, Mita E, Kato M, Miyoshi E.

Clin Chem Lab Med. 2015 Jan;53(1):95-102. doi: 10.1515/cclm-2014-0427.

PMID:
25060348
12.

Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.

Tan GS, Lim KH, Tan HT, Khoo ML, Tan SH, Toh HC, Ching Ming Chung M.

J Proteome Res. 2014 Nov 7;13(11):4833-46. doi: 10.1021/pr500229n. Epub 2014 Jun 30.

PMID:
24946162
13.

Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C.

Reddy A, May E, Ehrinpreis M, Mutchnick M.

World J Gastroenterol. 2013 Dec 28;19(48):9328-33. doi: 10.3748/wjg.v19.i48.9328.

14.

Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis.

Liu Z, Ling Q, Wang J, Xie H, Xu X, Zheng S.

Oncol Lett. 2013 Jul;6(1):125-129. Epub 2013 May 8.

15.

Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis.

Zhong Y, Yan J, Deng M, Hu K, Yao Z, Zou Y, Xu R.

Exp Biol Med (Maywood). 2013 Aug 1;238(8):866-73. doi: 10.1177/1535370213494654. Epub 2013 Jul 4.

PMID:
23828588
16.

The insulin-like growth factor-1 and expression of its binding protein‑3 in chronic hepatitis C and hepatocellular carcinoma.

Adamek A, Kasprzak A, Mikoś H, Przybyszewska W, Seraszek-Jaros A, Czajka A, Sterzyńska K, Mozer-Lisewska I.

Oncol Rep. 2013 Sep;30(3):1337-45. doi: 10.3892/or.2013.2546. Epub 2013 Jun 19.

PMID:
23784592
17.

Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients.

Shan SG, Gao YT, Xu YJ, Huang Y, Zhang Q, Zhai DK, Li JB, Wang FM, Jing X, Du Z, Wang YJ.

Hepatol Res. 2013 Nov;43(11):1199-210. doi: 10.1111/hepr.12078. Epub 2013 May 10.

PMID:
23607749
18.

Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection.

Gressner OA, Fang M, Li H, Lu LG, Gressner AM, Gao CF.

Clin Chim Acta. 2013 Jun 5;421:126-31. doi: 10.1016/j.cca.2013.02.029. Epub 2013 Mar 15.

PMID:
23501329
19.

Serum VEGF as a tumor marker in patients with HCV-related liver cirrhosis and hepatocellular carcinoma.

Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y.

Anticancer Res. 2013 Mar;33(3):1013-21.

PMID:
23482775
20.

Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma.

Zhang HJ, Yao DF, Yao M, Huang H, Wu W, Yan MJ, Yan XD, Chen J.

World J Gastroenterol. 2012 Nov 7;18(41):5897-904. doi: 10.3748/wjg.v18.i41.5897.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk